Crossmark Global Holdings’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-15,500
Closed -$20K 1398
2021
Q4
$20K Hold
15,500
﹤0.01% 1368
2021
Q3
$34K Hold
15,500
﹤0.01% 1400
2021
Q2
$58K Hold
15,500
﹤0.01% 1417
2021
Q1
$51K Hold
15,500
﹤0.01% 1413
2020
Q4
$53K Hold
15,500
﹤0.01% 1379
2020
Q3
$63K Hold
15,500
﹤0.01% 1329
2020
Q2
$52K Hold
15,500
﹤0.01% 1350
2020
Q1
$36K Hold
15,500
﹤0.01% 1244
2019
Q4
$56K Buy
15,500
+10
+0.1% +$81 ﹤0.01% 1388
2019
Q3
$128K Buy
15,490
+40
+0.3% +$324 ﹤0.01% 1314
2019
Q2
$133K Buy
15,450
+290
+2% +$2.59K ﹤0.01% 1358
2019
Q1
$162K Sell
15,160
-50
-0.3% -$535 ﹤0.01% 1350
2018
Q4
$133K Buy
15,210
+440
+3% +$5.61K ﹤0.01% 1352
2018
Q3
$248K Buy
14,770
+600
+4% +$13K 0.01% 1429
2018
Q2
$297K Buy
14,170
+1,060
+8% +$19.6K 0.01% 1313
2018
Q1
$211K Sell
13,110
-3,400
-21% -$67.4K 0.01% 1475
2017
Q4
$313K Buy
16,510
+1,420
+9% +$25.7K 0.01% 1337
2017
Q3
$212K Buy
+15,090
New +$137K 0.01% 1527
2016
Q3
$212K Buy
+15,090
New +$89.4K 0.01% 1526

Other funds holding SPPI

Crossmark Global Holdings's SPPI Position: Q1 2022 in Review

Crossmark Global Holdings sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q1 2022, closing a stake of 15,500 shares — an estimated $20K sold.

Crossmark Global Holdings first reported a position in SPPI in Q3 2016 and held it in 19 quarters. The position peaked at $313K in Q4 2017. 101 funds tracked by Wall St. Rank hold SPPI as of Q1 2022.

  • Crossmark Global Holdings reported no remaining Spectrum Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
  • Crossmark Global Holdings sold 15,500 Spectrum Pharmaceuticals Inc shares in Q1 2022, an estimated $20K.
  • Crossmark Global Holdings first reported a position in Spectrum Pharmaceuticals Inc in Q3 2016 and held it in 19 quarters.
  • Crossmark Global Holdings's Spectrum Pharmaceuticals Inc position peaked at $313K in Q4 2017.
  • 101 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q1 2022.

Based on Crossmark Global Holdings's 13F filing for Q1 2022, filed 11 May 2022.